research Aromatase inhibition by letrozole attenuates kainic acid-induced seizures but not neurotoxicity in mice
Letrozole reduces seizures but not brain damage in mice.
Search
for
Sort by
Research
270-300 / 1000+ results research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
Finasteride does not harm men's bone health.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Used Right, IV Arsenic Is Safe & Effective
Intravenous arsenic is safe and effective for treating certain blood cancers.
research Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Decision letter for "Repeated finasteride administration promotes synaptic plasticity and produces antidepressant‐ and anxiolytic‐like effects in female rats"
research Decision letter for "Repeated finasteride administration promotes synaptic plasticity and produces antidepressant‐ and anxiolytic‐like effects in female rats"
research Therapeutic Strategies to Target the Androgen Receptor
Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
research Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
Spironolactone is safe for treating female hair loss, but the safety of other drugs is uncertain.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research La clinoïdectomie antérieure extra-durale dans l'abord des méningiomes sus-tentoriels de la base du crâne. À propos d'une série de 142 cas
Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
research Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma
research Adverse effects at the level of marginal periodontium secondary to Finasteride administration
research Antiandrogenic drugs, a therapeutic option for frontal fibrosing alopecia patients
Antiandrogenic drugs could be a good treatment option for frontal fibrosing alopecia.
research An industry update: what’s new in the field of therapeutic delivery this month?
New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
Ritlecitinib works well and is safe for treating alopecia areata.
research Azathioprine
A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research P075 A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib was more effective than methotrexate for treating alopecia areata.